Cancer testis antigen expression in gastrointestinal stromal tumors: New markers for early recurrence
Daniel Perez
Department of Visceral and Transplant Surgery, University Hospital Zurich, Zurich, Switzerland
Daniel Perez and Thomas Herrmann contributed equally to this work.
Search for more papers by this authorThomas Herrmann
Medical Oncology, National Center for Tumor Diseases, University Hospital, Heidelberg, Germany
Daniel Perez and Thomas Herrmann contributed equally to this work.
Search for more papers by this authorAchim A. Jungbluth
Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan-Kettering Cancer Center, New York, NY
Search for more papers by this authorPierre Samartzis
Department of Visceral and Transplant Surgery, University Hospital Zurich, Zurich, Switzerland
Search for more papers by this authorGiulio Spagnoli
Department of Research, Institute for Surgical Research and Hospital Management, University Hospital, Basel, Switzerland
Search for more papers by this authorNicolas Demartines
Department of Visceral and Transplant Surgery, University Hospital Zurich, Zurich, Switzerland
Search for more papers by this authorPierre-Alain Clavien
Department of Visceral and Transplant Surgery, University Hospital Zurich, Zurich, Switzerland
Search for more papers by this authorSilvia Marino
Department of Pathology, University Hospital Zurich, Zurich, Switzerland
Search for more papers by this authorBurkhardt Seifert
Biostatistics Unit ISPM, University of Zurich, Zurich, Switzerland
Search for more papers by this authorCorresponding Author
Dirk Jaeger
Medical Oncology, National Center for Tumor Diseases, University Hospital, Heidelberg, Germany
Fax: +49-6221-56-7225.
Medical Oncology, NCT, University Hospital Heidelberg, Im Neuenheimer Feld 350, 69120 Heidelberg, GermanySearch for more papers by this authorDaniel Perez
Department of Visceral and Transplant Surgery, University Hospital Zurich, Zurich, Switzerland
Daniel Perez and Thomas Herrmann contributed equally to this work.
Search for more papers by this authorThomas Herrmann
Medical Oncology, National Center for Tumor Diseases, University Hospital, Heidelberg, Germany
Daniel Perez and Thomas Herrmann contributed equally to this work.
Search for more papers by this authorAchim A. Jungbluth
Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan-Kettering Cancer Center, New York, NY
Search for more papers by this authorPierre Samartzis
Department of Visceral and Transplant Surgery, University Hospital Zurich, Zurich, Switzerland
Search for more papers by this authorGiulio Spagnoli
Department of Research, Institute for Surgical Research and Hospital Management, University Hospital, Basel, Switzerland
Search for more papers by this authorNicolas Demartines
Department of Visceral and Transplant Surgery, University Hospital Zurich, Zurich, Switzerland
Search for more papers by this authorPierre-Alain Clavien
Department of Visceral and Transplant Surgery, University Hospital Zurich, Zurich, Switzerland
Search for more papers by this authorSilvia Marino
Department of Pathology, University Hospital Zurich, Zurich, Switzerland
Search for more papers by this authorBurkhardt Seifert
Biostatistics Unit ISPM, University of Zurich, Zurich, Switzerland
Search for more papers by this authorCorresponding Author
Dirk Jaeger
Medical Oncology, National Center for Tumor Diseases, University Hospital, Heidelberg, Germany
Fax: +49-6221-56-7225.
Medical Oncology, NCT, University Hospital Heidelberg, Im Neuenheimer Feld 350, 69120 Heidelberg, GermanySearch for more papers by this authorAbstract
Cancer testis antigens (CTAs) are expressed in a variety of malignant tumors but not in any normal adult tissues except germ cells and occasionally placenta. Because of this tumor-associated pattern of expression, CTAs are regarded as potential vaccine targets. The expression of CTAs in gastrointestinal stromal tumors (GIST) has not been analyzed systematically previously. The present study was performed to analyze the expression of CTA in GIST and to determine if CTA expression correlates with prognosis. Thirty-five GIST patients were retrospectively analyzed for their expression of CTAs by immunohistochemistry using the followingmonoclonal antibodies (mAb/antigen): MA454/MAGE-A1, M3H67/MAGE-A3, 57B/MAGE-A4, CT7-33/MAGE-C1 and E978/NY-ESO-1. Fourteen tumors (40%) expressed 1 or more of the 5 CTAs tested. Fourteen percent (n = 5/35) were positive for MAGE-A1, MAGE-A3 or MAGE-A4, respectively. Twenty-six percent (n = 9/35) stained positive for MAGE-C1 and 20% (n = 7/35) for NY-ESO-1. A highly significant correlation between CTA expression and tumor recurrence risk was observed (71% vs. 29%; p = 0.027). In our study population, the high-risk GIST expressed CTAs more frequently than low-risk GIST (p = 0.012). High-risk GISTs which stained positive for at least 1 CTA, recurred in 100% (n = 25) of the cases. This is the first study analyzing CTA expression in GIST and its prognostic value for recurrence. The CTA staining could add information to the individual patient prognosis and represent an interesting target for future treatment strategies. © 2008 Wiley-Liss, Inc.
References
- 1 Kirkin AF,Dzhandzhugazyan KN,Zeuthen J. Cancer/testis antigens: structural and immunobiological properties. Cancer Invest 2002; 20: 222–36.
- 2 Jungbluth AA,Chen YT,Busam KJ,Coplan K,Kolb D,Iversen K,Williamson B,Van Landeghem FK,Stockert E,Old LJ. CT7 (MAGE-C1) antigen expression in normal and neoplastic tissues. Int J Cancer 2002; 99: 839–45.
- 3 Scanlan MJ,Gordon CM,Williamson B,Lee SY,Chen YT,Stockert E,Jungbluth A,Ritter G,Jager D,Jager E,Knuth A,Old LJ. Identification of cancer/testis genes by database mining and mRNA expression analysis. Int J Cancer 2002; 98: 485–92.
- 4 Scanlan MJ,Gure AO,Jungbluth AA,Old LJ,Chen YT. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev 2002; 188: 22–32.
- 5 Jager D,Jager E,Knuth A. Immune responses to tumour antigens: implications for antigen specific immunotherapy of cancer. J Clin Pathol 2001; 54: 669–74.
- 6 Nakahara M,Isozaki K,Hirota S,Miyagawa J,Hase-Sawada N,Taniguchi M,Nishida T,Kanayama S,Kitamura Y,Shinomura Y,Matsuzawa Y. A novel gain-of-function mutation of c-kit gene in gastrointestinal stromal tumors. Gastroenterology 1998; 115: 1090–5.
- 7 Fletcher CD,Berman JJ,Corless C,Gorstein F,Lasota J,Longley BJ,Miettinen M,O'Leary TJ,Remotti H,Rubin BP,Shmookler B,Sobin LH, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Int J Surg Pathol 2002; 10: 81–9.
- 8 Miettinen M,Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 2006; 23: 70–83.
- 9 Dematteo RP,Gold JS,Saran L,Gönen M,Liau KH,Maki RG,Singer S,Besmer P,Brennan MF,Antonescu CR. Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). Cancer 2008; 112: 608–15.
- 10 Blay JY,Bonvalot S,Casali P,Choi H,Debiec-Richter M,Dei Tos AP,Emile JF,Gronchi A,Hogendoorn PC,Joensuu H,Le Cesne A,McClure J, et al. Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20–21 March 2004, under the auspices of ESMO. Ann Oncol 2005; 16: 566–78.
- 11 Jungbluth AA,Stockert E,Chen YT,Kolb D,Iversen K,Coplan K,Williamson B,Altorki N,Busam KJ,Old LJ. Monoclonal antibody MA454 reveals a heterogeneous expression pattern of MAGE-1 antigen in formalin-fixed paraffin embedded lung tumours. Br J Cancer 2000; 83: 493–7.
- 12 Chen YT,Gure AO,Tsang S,Stockert E,Jager E,Knuth A,Old LJ. Identification of multiple cancer/testis antigens by allogeneic antibody screening of a melanoma cell line library. Proc Natl Acad Sci USA 1998; 95: 6919–23.
- 13
Jungbluth AA,Busam KJ,Kolb D,Iversen K,Coplan K,Chen YT,Spagnoli GC,Old LJ.
Expression of MAGE-antigens in normal tissues and cancer.
Int J Cancer
2000;
85:
460–5.
10.1002/(SICI)1097-0215(20000215)85:4<460::AID-IJC3>3.0.CO;2-N CAS PubMed Web of Science® Google Scholar
- 14 Scanlan MJ,Welt S,Gordon CM,Chen YT,Gure AO,Stockert E,Jungbluth AA,Ritter G,Jager D,Jager E,Knuth A,Old LJ. Cancer-related serological recognition of human colon cancer: identification of potential diagnostic and immunotherapeutic targets. Cancer Res 2002; 62: 4041–7.
- 15 Kocher T,Schultz-Thater E,Gudat F,Schaefer C,Casorati G,Juretic A,Willimann T,Harder F,Heberer M,Spagnoli GC. Identification and intracellular location of MAGE-3 gene product. Cancer Res 1995; 55: 2236–9.
- 16 Miettinen M,Lasota J. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med 2006; 130: 1466–78.
- 17 Dow N,Giblen G,Sobin LH,Miettinen M. Gastrointestinal stromal tumors: differential diagnosis. Semin Diagn Pathol 2006; 23: 111–9.
- 18 DeMatteo RP. Treatment of advanced gastrointestinal stromal tumor: a marriage of targeted therapy and surgery? Ann Surg Oncol 2007; 14: 1–2.
- 19 Rutkowski P,Nowecki ZI,Michej W,Debiec-Rychter M,Wozniak A,Limon J,Siedlecki J,Grzesiakowska U,Kakol M,Osuch C,Polkowski M,Gluszek S, et al. Risk criteria and prognostic factors for predicting recurrences after resection of primary gastrointestinal stromal tumor. Ann Surg Oncol 2007; 14: 2018–27.
- 20 Siddiqui MA,Scott LJ. Imatinib: a review of its use in the management of gastrointestinal stromal tumours. Drugs 2007; 67: 805–20.
- 21 DeMatteo R,Owzar K,Maki R,Pisters P,Blackstein M,Antonescu C,Blanke C,Demetri G,von Mehren M,Ballman K and the American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study Team. Adjuvant imatinib mesylate increases recurrence free survival (RFS) in patients with completely resected localized primary gastrointestinal stromal tumor (GIST): North American Intergroup Phase III trial ACOSOG Z9001. J Clin Oncol 2007; 25(18S): 10079.
- 22 Scanlan MJ,Simpson AJ,Old LJ. The cancer/testis genes: review, standardization, and commentary. Cancer Immun 2004; 4: 1.
- 23 Bender A,Karbach J,Neumann A,Jäger D,Al-Batran SE,Atmaca A,Weidmann E,Biskamp M,Gnjatic S,Pan L,Hoffman E,Old LJ,Knuth A,Jäger E. LUD 00–009: phase 1 study of intensive course immunization with NY-ESO-1 peptides in HLA-A2 positive patients with NY-ESO-1-expressing cancer. Cancer Immun 2007; 7: 16.
- 24 Kruit WH,van Ojik HH,Brichard VG,Escudier B,Dorval T,Dréno B,Patel P,van Baren N,Avril MF,Piperno S,Khammari A,Stas M, et al. Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma. Int. J Cancer 2005; 117: 596–604.
- 25 Marchand M,Punt CJ,Aamdal S,Escudier B,Kruit WH,Keilholz U,Håkansson L,van Baren N,Humblet Y,Mulders P,Avril MF,Eggermont AM, et al. Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report. Eur J Cancer 2003; 39: 70–7.
- 26
Vansteenkiste J,Zielinski M,Dahabre J,Linder A,Malinowski W,Jassem J,Lopez-Brea M,Passlick B,Lehmann F,Brichard V.
Multi-center, double-blind, randomized, placebo-controlled phase II study to assess the efficacy of recombinant MAGE-A3 vaccine as adjuvant therapy in stage IB/II MAGE-A3-positive, completely resected, non-small cell lung cancer (NSCLC).
J. Clin. Oncol
2006;
24(18S):
7019.
10.1200/jco.2006.24.18_suppl.7019 Google Scholar
- 27
Landry C,Brasseur F,Spagnoli GC,Marbaix E,Boon T,Coulie P,Godelaine D.
Monoclonal antibody 57B stains tumor tissues that express gene MAGE-A4.
Int J Cancer
2000;
86:
835–41.
10.1002/(SICI)1097-0215(20000615)86:6<835::AID-IJC12>3.0.CO;2-N CAS PubMed Web of Science® Google Scholar
- 28
Rimoldi D,Salvi S,Schultz-Thater E,Spagnoli GC,Cerottini JC.
Anti-MAGE-3 antibody 57B and anti-MAGE-1 antibody 6C1 can be used to study different proteins of the MAGE-A family.
Int J Cancer
2000;
86:
749–51.
10.1002/(SICI)1097-0215(20000601)86:5<749::AID-IJC24>3.0.CO;2-O CAS PubMed Web of Science® Google Scholar
- 29 Segal NH,Blachere NE,Shiu HY,Leejee S,Antonescu CR,Lewis JJ,Wolchok JD,Houghton AN. Antigens recognized by autologous antibodies of patients with soft tissue sarcoma. Cancer Immun 2005; 5: 4.
- 30 Miettinen M,Virolainen M,Maarit Sarlomo R. Gastrointestinal stromal tumors–value of CD34 antigen in their identification and separation from true leiomyomas and schwannomas. Am J Surg Pathol 1995; 19: 207–16.
- 31 Nakamura N,Yamamoto H,Yao T,Oda Y,Nishiyama K,Imamura M,Yamada T,Nawata H,Tsuneyoshi M. Prognostic significance of expressions of cell-cycle regulatory proteins in gastrointestinal stromal tumor and the relevance of the risk grade. Hum Pathol 2005; 36: 828–37.
Citing Literature
